SCHEMBL4232172

SCHEMBL4232172

Cc1nn(-c2ccc(C#N)cc2)c(C)c1COc1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.54
CYP19A1 P11511 3/20 0.45
SLC34A1 Q06495 4/20 0.44
HTT P42858 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 1/20 0.43
ADRB2 P07550 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
NR1H4 Q96RI1 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4233150 0.94 AR (0.60) ARCYP19A1SLC34A1HTTNPSR1
SCHEMBL4241563 0.91 AR (0.52) ARSLC34A1NR1H4MEN1KMT2A
SCHEMBL4237759 0.90 AR (0.56) ARCYP19A1SLC34A1HTTNPSR1
SCHEMBL4234391 0.88 AR (0.53) ARSLC34A1
SCHEMBL4239003 0.88 AR (0.54) ARCYP19A1SLC34A1HTTNPSR1
SCHEMBL4233511 0.88 AR (0.70) ARSLC34A1CYP1A2KDM4E
SCHEMBL4230109 0.86 AR (0.56) ARSLC34A1
SCHEMBL4237455 0.86 AR (0.52) ARCYP19A1SLC34A1NPSR1SMN1; SMN2
SCHEMBL4241299 0.85 AR (0.60) AR
SCHEMBL4239402 0.85 AR (0.55) ARSLC34A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
WO-2009119880-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270361-A1 Substituted pyrazole derivatives and use thereof CBR3, CBR1, NOX5 AR 622/4885CYP19A1 940/4885SLC34A1 1375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.